The East Village Opera Company, by Georges Bizet, Alfredo Catalani, Leo Delibes, Wolfgang Amadeus Mozart, Giacomo Puccini, Henry Purcell, Giuseppe Verdi, Peter Kiesewalter, East Village Opera Company, and Orchestr Ceská Filharmonie -- $11.99
Nov. 1 (Bloomberg) -- Sanofi-Aventis SA's new diet pill, Acomplia, may get limited sales in Germany because the treatment is being targeted by a national plan to trim health-care spending.
Boston-based advertising agency Hill Holliday scored a major victory yesterday by landing ad duties for a top-selling high-blood pressure medication made by pharmaceutical giant Novartis, people familiar...
FTC allows generic drug company to buy rival, creating No. 3 firm. WASHINGTON (Reuters) -- Watson Pharmaceuticals Inc. $1.9 billion deal to acquire Andrx Corp. received U.S. antitrust approval Tuesday after the companies agreed to conditions aimed at preserving competition for some drugs.
The biotechnology sector has seen a burst of M&A activity over the past several months and analysts expect the trend to continue, as big pharmaceutical companies look to fill their pipelines by acquiring smaller biotech operations.
Boston-based advertising agency Hill Holliday won a huge piece of business from drug company Novartis - a blockbuster account, people familiar with the matter said. The Switzerland-based company, which...
DOR BioPharma, Inc. (OTCBB: DORB) ('DOR,' or the'Company') announced today that it has formed an alliance with theWadsworth Center of the New York State Department of Health in Albany, NewYork and Lovelace Respiratory Research Institute (LRRI) in Albuquerque, NM,to build upon expertise in testing RiVax(TM), DOR's recombinant vaccineagainst ricin toxin, to protect against inhalation and oral toxin
(PRWEB) October 27, 2006 -- A Federal Court in Pennsylvania preserved victims' rights and denied a drug manufacturer's request to allow it to hide behind the FDA.
US District Court ruling allows parents of cancer victim to proceed in their litigation against Elidel manufacturer Novartis Pharmaceuticals. Novartis' Motion to Dismiss was denied after their argument that FDA labeling regulations prevented their notification of physicians and patients was deemed to be invalid. This landmark decision will have lasting impact on product and drug liability cases